Annovis Stock Today

ANVS -  USA Stock  

USD 13.04  0.49  3.62%

Market Performance
0 of 100
Odds Of Distress
Over 94
Annovis Bio is selling at 13.04 as of the 23rd of January 2022; that is -3.62 percent decrease since the beginning of the trading day. The stock's lowest day price was 12.96. Annovis Bio has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Annovis Bio are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of February 2020 and ending today, the 23rd of January 2022. Click here to learn more.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania. Annovis Bio operates under Biotechnology classification in the United States and is traded on NYSEMKT Exchange. The company has 8.1 M outstanding shares of which 428.35 K shares are presently shorted by private and institutional investors with about 3.21 trading days to cover. More on Annovis Bio

Annovis Bio Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Annovis Bio's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Annovis Bio or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Annovis Bio generated a negative expected return over the last 90 days
Annovis Bio has high historical volatility and very poor performance
Annovis Bio has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 366.66 K. Net Loss for the year was (10.28 M) with profit before overhead, payroll, taxes, and interest of 173.72 K.
Annovis Bio currently holds about 47.46 M in cash with (8.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.86.
Annovis Bio has a frail financial position based on the latest SEC disclosures
Roughly 31.0% of the company shares are held by company insiders
Latest headline from Insiders might want to re-evaluate their US658k stock purchase as Annovis Bio, Inc. drops to US117m - Nasdaq
Annovis Bio Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Annovis Bio SEC Filings
Annovis Bio SEC Filings Security & Exchange Commission EDGAR Reports
Legal NameAnnovis Bio
Chairman, CEO and PresWeixing Wang  (View All)
Average Analyst Recommendation
Analysts covering Annovis Bio report their recommendations after researching Annovis Bio's financial statements, talking to executives and customers, or listening in on Annovis Bio's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Annovis Bio. The Annovis consensus assessment is calculated by taking the average forecast from all of the analysts covering Annovis Bio.
Strong Buy1 Opinion
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Annovis Bio based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Annovis Bio financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 3 - FrailDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares7.8 M7.3 M
Significantly Up
Slightly volatile
Weighted Average Shares Diluted7.8 M7.3 M
Significantly Up
Slightly volatile
Total Assets10.1 M9.3 M
Significantly Up
Slightly volatile
Total Liabilities682.6 K665.1 K
Fairly Up
Current Assets10.1 M9.3 M
Significantly Up
Slightly volatile
Current Liabilities959.3 K665.1 K
Way Up
Slightly volatile
Total Debt447.2 K449.8 K
Slightly Down
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Annovis Bio's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong SellUndervalued
Financial Strength
Annovis Bio's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Annovis Bio's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Annovis Bio's financial leverage. It provides some insight into what part of Annovis Bio's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Annovis Bio's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Annovis Bio deploys its capital and how much of that capital is borrowed.
Annovis Bio cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. As of 01/23/2022, Debt to Equity Ratio is likely to grow to 0.1. Also, Average Equity is likely to grow to about 11.4 MThe company has a current ratio of 41.67, suggesting that it is liquid enough and is able to pay its financial obligations when due.

Operating Cash Flow

(3.67 Million)Share
Annovis Bio (ANVS) is traded on NYSEMKT Exchange in USA. It is located in 1055 Westlakes Drive and employs 2 people. Annovis Bio is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with current market capitalization of 105.63 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Annovis Bio's market, we take the total number of its shares issued and multiply it by Annovis Bio's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Annovis Bio conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 8.1 M outstanding shares of which 428.35 K shares are presently shorted by private and institutional investors with about 3.21 trading days to cover. Annovis Bio currently holds about 47.46 M in cash with (8.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.86.
Check Annovis Bio Probability Of Bankruptcy
The market capitalization of Annovis Bio is $105.63 Million. Annovis Bio retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.

Ownership Allocation (%)

Check Annovis Ownership Details

Annovis Stock Price Odds Analysis

What are Annovis Bio's target price odds to finish over the current price? In regard to a normal probability distribution, the odds of Annovis Bio jumping above the current price in 90 days from now is roughly 96.0%. The Annovis Bio probability density function shows the probability of Annovis Bio stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.8493. This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Annovis Bio will likely underperform. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Annovis Bio is significantly underperforming DOW.
 Odds Down 13.04HorizonTargetOdds Up 13.04 
3.66%90 days
Based on a normal probability distribution, the odds of Annovis Bio to move above the current price in 90 days from now is roughly 96.0 (This Annovis Bio probability density function shows the probability of Annovis Stock to fall within a particular range of prices over 90 days) .

Annovis Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Annovis Bio that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Annovis Bio's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Annovis Bio's value.
InstituionSecurity TypeTotal SharesValue
Vanguard Group IncCommon Shares229.5 K7.3 M
Voloridge Investment Management LlcCommon Shares108.7 K3.5 M
View Annovis Bio Diagnostics

Annovis Bio Historical Income Statement

Annovis Bio Income Statement is one of the three primary financial statements used for reporting Annovis's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Annovis Bio revenue and expense. Annovis Bio Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Annovis Bio Interest Expense is relatively stable at the moment as compared to the past year. Annovis Bio reported last year Interest Expense of 54,308.75. As of 01/23/2022, Operating Expenses is likely to grow to about 8.2 M, while Earning Before Interest and Taxes EBIT is likely to drop (5 M). View More Fundamentals

Annovis Stock Against Markets

Picking the right benchmark for Annovis Bio stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Annovis Bio stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Annovis Bio is critical whether you are bullish or bearish towards Annovis Bio at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Annovis Bio without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Center Now


Portfolio Center

All portfolio management and optimization tools to improve performance of your portfolios
All  Next Launch Module

Annovis Bio Corporate Executives

Elected by the shareholders, the Annovis Bio's board of directors comprises two types of representatives: Annovis Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Annovis. The board's role is to monitor Annovis Bio's management team and ensure that shareholders' interests are well served. Annovis Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Annovis Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
Please continue to Trending Equities. Note that the Annovis Bio information on this page should be used as a complementary analysis to other Annovis Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Complementary Tools for Annovis Stock analysis

When running Annovis Bio price analysis, check to measure Annovis Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annovis Bio is operating at the current time. Most of Annovis Bio's value examination focuses on studying past and present price action to predict the probability of Annovis Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Annovis Bio's price. Additionally, you may evaluate how the addition of Annovis Bio to your portfolios can decrease your overall portfolio volatility.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Bond Directory
Find actively traded corporate debentures issued by US companies
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Is Annovis Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Annovis Bio. If investors know Annovis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Annovis Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Annovis Bio is measured differently than its book value, which is the value of Annovis that is recorded on the company's balance sheet. Investors also form their own opinion of Annovis Bio's value that differs from its market value or its book value, called intrinsic value, which is Annovis Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Annovis Bio's market value can be influenced by many factors that don't directly affect Annovis Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Annovis Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Annovis Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Annovis Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.